United Kingdom Precision Medicine Market Insight
The United Kingdom Precision Medicine Market is growing at an 18.7% CAGR, driven by genomics integration, rising chronic disease burden, NHS-led personalized care initiatives, expanding biomarker-based therapies, and advances in AI-enabled diagnostics improving treatment precision and patient outcomes..
United Kingdom Precision Medicine Market Insights Forecasts to 2035
- The United Kingdom Precision Medicine Market Size Was Estimated at USD 3.8 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 18.7% from 2025 to 2035
- The United Kingdom Precision Medicine Market Size is Expected to Reach USD 21.1 Billion by 2035
Notable Insights for United Kingdom Precision Medicine Market
- By technology, genomics and sequencing technologies dominated, accounting for approximately 42–46% share in 2024, driven by large-scale genome initiatives.
- By application, oncology led with around 50–55% share, supported by increasing adoption of targeted cancer therapies and companion diagnostics.
- Approximately 1 in 17 people in the UK are estimated to be affected by rare diseases, many of which benefit from precision medicine approaches and genomic diagnostics.
- Around 60–70% of advanced cancer treatments in the UK increasingly rely on biomarker-guided or personalized therapy selection.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Precision Medicine Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Precision Medicine Market
- Illumina
- Thermo Fisher Scientific
- Roche
- AstraZeneca
- GlaxoSmithKline
- Qiagen
- Novartis
- Pfizer
- Others
Recent Developments:
- In May 2025, NHS England launched nationwide liquid biopsy (ctDNA) testing for lung and advanced breast cancer, enabling a “blood test first” approach to accelerate precision oncology and targeted treatment decisions.
- In November 2023: UK Parliament House of Lords Science and Technology Committee examined AI use in healthcare, highlighting opportunities in diagnostics and personalized medicine to support NHS innovation and precision medicine adoption.
Market Segmentation:
United Kingdom Precision Medicine Market, By Technology
- Genomics & Sequencing
- Bioinformatics
- Companion Diagnostics
- Others
United Kingdom Precision Medicine Market, By Application
- Oncology
- Rare Diseases
- Infectious Diseases
- Others
United Kingdom Precision Medicine Market, By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Institutions
United Kingdom Precision Medicine Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Precision Medicine Market is poised for strong growth, supported by national genomics programs, NHS integration, and rising demand for personalized therapies. Experts emphasize that oncology and rare disease applications will remain key growth drivers, leveraging biomarker-based diagnostics and targeted treatments. Continued investments in genomic sequencing infrastructure, AI-driven data analytics, and collaborative research initiatives are expected to accelerate innovation. Additionally, policy support and expanded patient access to precision diagnostics will further strengthen market development through 2035.